Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Bevacizumab + Tocilizumab in Advanced Hepatocellular Carcinoma
KCT0011783Phase 2Not yet recruiting
- Sponsor
- Celltrion
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of atezolizumab, bevacizumab and tocilizumab in hepatocellular carcinoma (HCC), sponsored by Celltrion. Planned start May 2026; status: not yet recruiting.
02
Drugs
atezolizumabbevacizumabtocilizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0011783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011783.